Navigation Links
Raptor Pharmaceuticals Doses First Patient in Phase 2b Clinical Trial of DR Cysteamine for Cystinosis
Date:6/1/2009

ounced the initiation of a Phase 2a clinical study of cysteamine bitartrate in NASH patients, in collaboration with UCSD. In November, 2008 Raptor announced a collaboration with Centre Hospitalier Universitaire d'Angers, in France, to study DR Cysteamine in Huntington's Disease, a rare, genetic neurological disease.

About Raptor Pharmaceuticals Corp.

Raptor Pharmaceuticals Corp. ("Raptor") is dedicated to speeding the delivery of new treatment options to patients by working to improve existing therapeutics through the application of highly specialized drug targeting platforms and formulation expertise. Raptor focuses on underserved patient populations where it can have the greatest potential impact. Raptor currently has product candidates in clinical development to treat nephropathic cystinosis, non-alcoholic steatohepatitis ("NASH"), Huntington's Disease ("HD"), and aldehyde dehydrogenase ("ALDH2") deficiency.

Raptor's preclinical programs are based upon bioengineered novel drug candidates and drug-targeting platforms derived from the human receptor-associated protein ("RAP") and related proteins that are designed to target cancer, neurodegenerative disorders and infectious diseases.

For additional information, please visit www.raptorpharma.com.

FORWARD LOOKING STATEMENTS

This document contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future results of operation or future financial performance, including, but not limited to the following statements: that Raptor will be able to fully enroll and complete the clinical trial in cystinosis patients; that data will be available in the third quarter of 2009; that Raptor will start a Phase 3 clinical trial in cystinosis
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
2. Raptor Pharmaceuticals Expands Board of Directors and Scientific Advisory Board
3. Raptor Pharmaceuticals Closes $10 Million Private Placement
4. Raptor Pharmaceuticals Corp. Announces Presentation at 5th International Cystinosis Conference 2008
5. Raptor Pharmaceuticals Corp. To Present at BIO 2008 International Convention
6. Raptor Pharmaceuticals Corp. Receives FDA Orphan Drug Designation for Cysteamine in Huntingtons Disease
7. Raptor Pharmaceuticals Corp. Enters Agreements to Advance Clinical Pipeline
8. Raptor Pharmaceuticals Acquires Orphan Clinical Program
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
11. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014 Five American winners ... Al Maktoum Awards for Medical Sciences", in its 8 ... Arab Emirates , on 15 December 2014. ... The Carter Center which won the Hamdan Award ... in numerous programs that aim to improve health and ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... on developing diagnostic tests for cancer and other conditions, today ... be presented at the Science for Business BioWin Day 2014, ... . The data come from VolitionRx,s lung cancer pilot ... department of the Centre Hospitalier Universitaire (CHU) de Liege in ...
(Date:11/24/2014)... , Nov. 24, 2014   Veracyte, Inc. ... H. Anderson , president and chief executive officer, will present ... th Annual Healthcare Conference on Tuesday, December 2, 2014 ... . The live audio webcast and subsequent replay ... . Please connect to the website at least 15 minutes ...
(Date:11/24/2014)... Continental Clinical Solutions, LLC (Continental) ... trials at its mid-Atlantic late-phase research facility, located ... with the idea of closing patient disparities in ... medical advances," said Continental's CEO, Saleh Stevens ... immortal cell line of Henrietta Lacks, dubious ethical ...
Breaking Biology Technology:Five US Winners Among Recipients of Hamdan Medical Awards 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6Veracyte to Present at the Piper Jaffray 26th Annual Healthcare Conference 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 2At Continental Clinical Solutions, CEO Saleh Stevens Focuses on Diversity in Clinical Trial Recruitment at Maryland Site 3
... developed a device platform that combines electronic components for ... an ultrathin skin-like patch that mounts directly onto the ... temporary tattoo. Led by researcher John A. Rogers, ... University of Illinois, the researchers described their novel skin-mounted ...
... Neb., Aug. 11, 2011 Transgenomic, Inc. (OTC/BB: TBIO) today ... June 30, 2011 and provided a business update. Second ... were $7.7 million, an increase of 50 percent compared with ... was $4.6 million or 59 percent of net sales, compared ...
... Inc. (Nasdaq: GNVC ) today announced that its ... Rights Plan through the adoption of a new Rights Agreement. ... September 7, 2011, which is the date that GenVec,s existing ... was adopted in connection with the expiration of the existing ...
Cached Biology Technology:Smart skin: Electronics that stick and stretch like a temporary tattoo 2Smart skin: Electronics that stick and stretch like a temporary tattoo 3Transgenomic Reports Second Quarter Financial Results 2Transgenomic Reports Second Quarter Financial Results 3Transgenomic Reports Second Quarter Financial Results 4Transgenomic Reports Second Quarter Financial Results 5Transgenomic Reports Second Quarter Financial Results 6Transgenomic Reports Second Quarter Financial Results 7Transgenomic Reports Second Quarter Financial Results 8Transgenomic Reports Second Quarter Financial Results 9GenVec Renews Stockholder Rights Plan 2GenVec Renews Stockholder Rights Plan 3
(Date:11/21/2014)... JOSE, Calif. , Nov. 20, 2014   ... global leader in microcontroller (MCU) and touch technology solutions, ... digital temperature sensors with the widest V cc ... delivers higher temperature accuracy and faster I 2 C ... registers and serial EEPROM memory making them ideal for ...
(Date:11/18/2014)... Md. , Nov. 17, 2014 The Parenteral ... and U.S. regulatory agencies will speak and at least seven ... Metrics Conference at the Omni Shoreham Hotel in ... pleased once again to have significant support from the regulatory ... Europe in our effort to help ...
(Date:11/12/2014)... Fla. , Nov. 12, 2014 Crossmatch™, ... today that its U.are.U ® fingerprint readers have ... chain in Central Mexico . The ... 2014 to eliminate payroll issues caused by employees clocking ... installing the U.are.U fingerprint readers, Montparnasse relied on paper ...
Breaking Biology News(10 mins):Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... 1:00 p.m. ET) Research published in Nature Chemical Biology ... pathway, termed necroptosis, all target and inhibit RIP1 kinase, ... by trauma such as a heart attack or stroke, ... damage contributing to death or long-term disability. The findings ...
... nuts included in a heart healthy diet reduced low-density ... with qualified health claims, according to researchers. "We looked ... in the health claim for tree nuts, while other ... heart healthy diet," says Dr. Amy E. Griel, a ...
... the mid-1970s, Glenn Shaw of the Geophysical Institute at ... of Arctic haze after collecting aerosol samples from Barrow, ... contain relatively pure air due to its remote locale ... Shaws data indicated there was a murky cloud of ...
Cached Biology News:Stopping unwanted cell death: Implications for drug discovery 2Stopping unwanted cell death: Implications for drug discovery 3Macadamia nuts can be included in heart healthy diet 2Atmospheric scientists gear up for collaborative airborne campaigns 2
MOUSE ANTI PROTEIN KINASE C BETA 2 Immunogen: Protein kinase C beta 2...
SHEEP ANTI DEHYDROEPIANDROSTERONE...
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D.M. Gersten (1996) Provides comprehensive descriptions of the techniques available for analytical gel electrophoresis of proteins and offers clear step-by-step protocols for all of the m...
Biology Products: